因流量过大，本站目前购买的空间和带宽已经无法支撑用户的正常访问。
现诚寻空间服务提供商，要求能够免费提供足够的带宽和空间。有愿意提供服务器空间和带宽支持的请联系：admin@vctoday.com，谢谢
今日VC（Vctoday.com）创建于2008年，致力于提供最有价值的风险投资资讯信息服务，服务于创业者和风险投资商。
在2010年里，我们将加强原创报道，全面关注中国（China）的风险投资和私募股权基金发展。并将针对行业细分化，正式推出游戏频道，记录中国数字娱乐产业的前进历程。也热烈欢迎对此有兴趣的相关人士加盟到我们的队伍中。有意者请将您的简历发送到admin@vctoday.com，最基本的要求是善于归纳总结，写作水平娴熟，英语水平能够达到正常读写。
Behrooz Parsay Joins the Company as Senior Vice President of Engineering and Operations
SANTA CLARA,, Calif., February 1, 2010-– SpiderCloud® Wireless, Inc., a developer of wireless technologies and the pioneer of the Enterprise Radio Access Network (E-RAN) platform developed for mobile operators, today announced the closing of its Series B financing round. The $25 million round was led by Opus Capital along with new investments from Shasta Ventures and existing Series A investors Charles River Ventures and Matrix Partners.
“Investing in SpiderCloud Wireless means investing in a solution to address the network capacity issues facing mobile operators today,” said Rob Coneybeer, managing director at Shasta Ventures. “The indoor wireless E-RAN platform has the potential to change how radio access networks are deployed for years to come.”
The company also announced the addition of Behrooz Parsay as its new senior vice president of engineering and operations. Mr. Parsay has over 20 years experience in bringing wire-line and wireless products and systems to market and has previously held RF engineering and management positions with Aperto Networks, Ericsson, DIVA, Kestrel, and Lantern Communications. Mr. Parsay holds a Bachelor of Science in Electrical Engineering from Chico State University and a Master of Science in Engineering Management from Santa Clara University.
“SpiderCloud Wireless is unique in its approach to solving the indoor capacity and coverage problems for mobile operators,” said Behrooz Parsay. “I’m excited to join a company comprised of so many people with proven success in the wireless industry and look forward to making my contributions to the company, its customers and partners.”
“Behrooz Parsay is a great addition to our team and with his broad network experience, I am confident that we will deliver a world-class system to our valued customers,” said Peter Wexler, co-founder and board member of SpiderCloud Wireless. “I have had the pleasure of pulling together an outstanding engineering team to develop the initial product and look forward to making continued contributions to the company.”
“We are excited to start the New Year on a high note with investments secured and a well-rounded executive team,” said Michael Gallagher, CEO of SpiderCloud Wireless, Inc. “The funds will allow SpiderCloud to deepen its partnerships with enterprise solution providers to introduce a new class of mobile Internet services.”
SpiderCloud Wireless is speaking at Mobile World Congress in Barcelona, February 15-18. Michael Gallagher, CEO, will participate on the panel, “Taking Enterprise Solutions to Market,” which is taking place on Wednesday, February 17 at 14:00 (CET).
SpiderCloud Wireless’ E-RAN platform is a scalable system comprised of a SmartCloud® Services Node (SCSN) and Radio Nodes (SCRN). Advanced features bring ‘zero touch’ installation and low-cost routing options for voice and data to the world of mobile radio access networks. The result is a purpose-built and self-organizing wireless network capable of extending the enterprise’s full suite of voice and data applications and services to any standard handset or computing device. E-RAN brings together the functionality and security of cellular networks with the utility and economics of enterprise Wi-Fi data networks.
About SpiderCloud Wireless, Inc.
SpiderCloud Wireless, Inc. is a developer of wireless technologies and the pioneer of the Enterprise Radio Access Network (E-RAN) platform. The company is privately funded and is located at 2500 Augustine Drive, Suite 200, Santa Clara, CA 95054. USA. www.spidercloud.com
SpiderCloud and SmartCloud are registered trademarks of SpiderCloud Wireless, Inc. ©2010 SpiderCloud Wireless, Inc. All rights reserved.
Preferred Stock Purchase to Help Company Grow and Invest in Technology and Service Innovations
NEW YORK, January 29, 2010– EDGAR® Online, Inc. (Nasdaq: EDGR), a leader in the distribution of public company filings and in the XBRL financial reporting standard, today announced that it has completed an agreement for Bain Capital Ventures to purchase $12 million worth of convertible Series B Preferred Stock of the Company. EDGAR Online expects to use the newly-secured funding to scale its pioneering leadership position in the filing business associated with XBRL, the eXtensible Business Reporting Language standard, and simultaneously invest to expand its data and subscription offerings.
Bain Capital Ventures is an affiliate of Bain Capital, one of the largest and most respected private investment firms in the world. Bain Capital Ventures is known for its exceptional approach to identifying and partnering with the management teams of early and growth stage entrepreneurial companies to build market leaders. The firm has invested in such industry-leading companies as Gartner Group, SunGard, Experian, Archer Technologies, SolarWinds, DoubleClick, Instinet, Staples, ProfitLogic, Regulatory Data Corporation, Shopping.com, Taleo, LinkedIn and others. The Jordan, Edmiston Group acted as advisor to EDGAR Online in connection with the transaction.
“We are excited by the growth opportunity this investment by Bain Capital presents to our company, our customers and our shareholders,” said Philip Moyer, CEO of EDGAR Online. “This investment accelerates our ability to scale in support of the growing demands we see in our XBRL filings business and to deliver the next round of innovation we believe is needed in our data and subscriptions businesses. We cannot imagine a better strategic investor than Bain Capital, which has a long track record of success with hundreds of portfolio companies that understand and use compliance services, and others that drive software and service innovation across the entire financial services market. This investment not only strengthens our balance sheet, it also positions us to deliver the next generation of value for our shareholders.”
Two representatives of Bain Capital, Jeffrey Schwartz and John Connolly, will be joining EDGAR Online’s Board of Directors. Schwartz is a Founding Partner and Managing Director of Bain Capital Ventures, and Connolly is an Operating Partner. Connolly is the former CEO of Institutional Shareholder Services, a subsidiary of RiskMetrics which provides proxy voting, corporate governance, compliance, and risk management solutions.
“We are looking forward to Jeff and John joining our board,” Moyer added. “They both have a significant history of success in growing great companies in the compliance and financial services markets. Our work with Jeff and John and their colleagues over the past several months has demonstrated to us that they understand the needs of emerging market leaders like EDGAR Online and the full market opportunity we have in front of us.”
“We are excited to have the opportunity to make this investment because we believe EDGAR Online is a high potential company and a unique leader in its markets,” said Schwartz. “We have been very impressed with the technology, people and processes the Company has deployed to achieve market leadership in the XBRL filings market, and with the vision for its data and subscription assets. We believe we can bring tangible support and experience to EDGAR Online’s strategic vision and help their team accelerate growth and innovation for the benefit of their customers.”
EDGAR Online will be holding an investor call to discuss this announcement at 1:00 p.m. EST today. Philip Moyer, CEO and President, and John Ferrara, CFO, will host the call. To participate, please call (877) 407-8031 (toll-free for domestic callers) or (201) 689-8031 (international callers). The call will also be broadcast simultaneously over the Internet at: http://www.edgar-online.com/investor.
The teleconference replay will be available for approximately one week beginning at 7:00 p.m. EST on January 29 by calling (877) 660-6853 (domestic) or (201) 612-7415 (international callers). The account number is 286 and the conference ID is 343834.
About EDGAR Online, Inc.
EDGAR Online, Inc. (Nasdaq: EDGR) is a leader in the distribution of company data and public filings for equities, mutual funds and a variety of other publicly traded assets. The company delivers its information products directly to end users via online subscriptions and data licenses, and to redistributors who embed its content in their own and their clients’ Web sites.
EDGAR Online’s proprietary automated systems allow for the rapid conversion of data, and the company is a pioneer and leader in the global financial reporting standard eXtensible Business Reporting Language, otherwise known as XBRL. EDGAR Online uses its automated processing platform and expertise in XBRL to produce both datasets and tools and to assist organizations with the creation, management and distribution of XBRL financial reports. For more detailed information, please visit www.edgar-online.com.
About Bain Capital Ventures
Bain Capital Ventures (www.baincapitalventures.com) is the Boston-based venture capital affiliate of Bain Capital, which has approximately $65 billion of assets under management worldwide. Founded in 1984, Bain Capital and its affiliates have made investments in more than 300 companies. The firm’s history of investing in early stage companies also dates back to 1984, having made over 125 venture-stage investments since inception including such companies as Gartner Group, SunGard, Experian, Archer Technologies, SolarWinds, DoubleClick, Instinet, Staples, ProfitLogic, Regulatory Data Corporation, Shopping.com, Taleo, and LinkedIn. In 2001, Bain Capital Ventures was formed as a separate arm of Bain Capital to focus exclusively on growth investments. Bain Capital Ventures currently has approximately $1.5 billion in assets under management.
Use of Forward-Looking Statements
“Forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events and/or our future financial performance and include, without limitation, statements regarding our future growth prospects, future demand for our XBRL business, future innovations in our data and subscriptions business, and the impact of the investment by Bain Capital Ventures on any of those developments. These statements are only predictions and may differ materially from actual future events or results. EDGAR Online, Inc. disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. Please refer to the documents filed by EDGAR Online, Inc. with the Securities and Exchange Commission, which identify important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with our ability to (i) increase revenues, (ii) obtain profitability, (iii) obtain additional financing, (iv) changes in general economic and business conditions (including in the online business and financial information industry), (v) actions of our competitors, (vi) the extent to which we are able to develop new services and markets for our services, (vii) the time and expense involved in such development activities, (viii) risks in connection with acquisitions, (ix) the level of demand and market acceptance of our services, and (x) changes in our business strategies.
EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.
CHARLOTTESVILLE, Va., January 29, 2010– Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million. The financing was a combination of private equity and convertible notes to existing investors. Proceeds will support the company’s ongoing operations, including completion of a Phase I/II clinical trial in peripheral arterial disease (PAD) patients for its lead drug compound, trans sodium crocetinate (TSC).
“The successful financing in 2009 gives us the ability to complete our ongoing clinical trial in PAD and position the company for critical post proof-of-concept activities,” said David G. Kalergis, Chief Executive Officer.
Since its founding, Diffusion Pharmaceuticals has raised a total of $21.7 million to date including $19.1 million in private funds, and $2.6 million in Department of Defense research and development contracts.
About Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke, and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. A Phase I study in healthy subjects for Diffusion’s lead molecule, trans sodium crocetinate (TSC), was successfully completed in 2007. The company is currently completing enrollment in a Phase I/II dose-range-finding, safety and efficacy study of TSC in peripheral arterial disease patients suffering from intermittent claudication. This study is designated NCT00725881 on the clinicaltrials.gov Website. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit www.diffusionpharma.com .
Proceeds Will Further Advance Liprotamase Commercialization Efforts
CAMBRIDGE, Mass., January 28, 2010– Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.
“We are delighted to welcome both MPM as an investor and Ashley as a board member and we are grateful for the continued support from our existing investors,” stated Alexey Margolin, Ph.D., chief executive officer of Alnara. “This financing serves as an important external validation of the significant market opportunity for liprotamase and our pre-clinical platform, and provides us with the resources to expand our commercialization efforts in the rapidly growing pancreatic enzyme replacement therapy (PERT) market. This is going to be a very exciting year for Alnara, and we remain on track to file a new drug application (NDA) for liprotamase with the U.S. Food and Drug Administration in the first quarter of this year.”
“I am honored to join the Alnara board,” stated Dr. Dombkowski. “This round of funding increases financial flexibility for Alnara as the company prepares to commercialize liprotamase. As a recombinant product with positive long-term safety and nutritionally relevant data, liprotamase helps to address many of the unmet needs in this dynamic therapeutic area. This strong product profile, combined with the NDA filing planned for this quarter, positions Alnara on the cusp of significant value creation opportunities.”
Rich Aldrich, chairman of the board of Alnara commented, “We believe the regulatory approval and launch of liprotamase as a non-porcine PERT will represent a new paradigm in the treatment of pancreatic insufficiency. Over the last year, Alnara has transformed from a start-up company to a leader in protein therapeutics preparing to commercialize a potentially breakthrough product in liprotamase. Alexey and his team have done a phenomenal job advancing the development program for liprotamase and continuing the collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) as we prepare to bring this much needed new therapy to patients.”
Proceeds from the financing will be used to continue to advance the regulatory filings, commercial planning and launch preparation efforts in support of liprotamase for the treatment of exocrine pancreatic insufficiency and to advance the company’s pre-clinical platform. The company also plans to use proceeds to finalize development of a novel pediatric formulation which meets a significant unmet need in patients with cystic fibrosis (CF). Overall health in people living with pancreatic insufficiency is directly related to their nutritional status and survival.
About Liprotamase & Pancreatic Enzyme Replacement Therapy (PERT)
Liprotamase is a novel, oral, non-porcine pancreatic enzyme replacement therapy designed to treat maldigestion, malabsorption and malnutrition as a result of exocrine pancreatic insufficiency associated with cystic fibrosis chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic diseases. Patients with pancreatic insufficiency cannot properly digest and absorb fat, protein, and carbohydrates preventing adequate nutrient absorption. PERT is a life-saving treatment involving the administration of pancreatic enzymes. Alnara believes liprotamase may have the potential to overcome the challenges and issues associated with currently available therapies, by reducing pill burden, providing a formulation for patients unable to swallow capsules and removing the risk for viral contamination thereby providing a first-in-class non-porcine produced PERT. Cystic fibrosis is a life-threatening genetic disease that affects approximately 30,000 children and adults in the United States and nearly 100,000 people worldwide.
Results from an international, Phase 3 open-label, long-term safety study presented at the North American Cystic Fibrosis Conference in October demonstrated the safety and nutritional benefits of liprotamase. The nutritional parameters measured during the study showed nutritional maintenance relative to the U.S. population, which is a major finding for this historically challenged patient group, as well as a significantly reduced pill burden. Approximately 90 percent of CF patients receive PERT to improve nutritional status and bowel-related symptoms related to pancreatic insufficiency. Alnara expects to file a new drug application for liprotamase with the U.S. Food and Drug Administration in the first quarter of 2010.
About MPM Capital
MPM Capital is one of the world’s largest life science-dedicated venture investors. With committed capital under management of $2.3 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.
About Alnara
Alnara Pharmaceuticals, Inc. is dedicated to developing and commercializing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara’s lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The company is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Cambridge, Massachusetts, Alnara is backed by an experienced management team and top-tier venture investors, including Third Rock Ventures, Frazier Healthcare, MPM Capital and Bessemer Venture Partners. For more information, please visit the company’s website at www.alnara.com.
Contact:
Pure Communications Inc.
Sheryl Seapy, 949-608-0841
or
Alnara Pharmaceuticals
Robert Gallotto, 617-349-3690
Chief Business Officer
GREENWOOD VILLAGE, Colo., January 28, 2010– Keating Capital, Inc. announced today that it made its first portfolio investment on January 25, 2010: a $1 million investment in Preferred Stock of NeoPhotonics Corporation.
NeoPhotonics is a San Jose, California and Shenzhen, China-based developer and manufacturer of photonic integrated circuit based components, modules and subsystems for use in telecommunications networks.
About Keating Capital, Inc.
Keating Capital (www.KeatingCapital.com) is a business development company focused on making minority, non-controlling equity investments in private businesses that are seeking growth capital and are committed to, and capable of, becoming public. Keating Capital seeks to make its investments at a 50% discount to comparable public companies.
About NeoPhotonics Corporation
NeoPhotonics Corporation (www.NeoPhotonics.com) is a leading developer and vertically integrated manufacturer of photonic integrated circuit (PIC) based components, modules and subsystems for use in telecommunications networks. The Company’s products include active semiconductor, passive PLC and MEMS multi-dimensional switching functions in a single product. This integration is enabled by nanomaterials and nanoscale design and fabrication technologies. Backed by leading venture capital firms and institutional investors, NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2000 certified engineering and manufacturing facilities in Silicon Valley and Shenzhen, China.
In 2009 the Company received the following honors in recognition of its ongoing success: the Deloitte “Technology Fast 50″ for Silicon Valley, the “Inc. 500″ Fastest Growing Private Companies, and the Red Herring “North America 100″ of Most Promising Tech Companies.
Contact:
Keating Capital, Inc.
Kyle Rogers, 720-889-0139
